{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:43:45Z","timestamp":1789681425182,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40262-025-01476-6","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:47:10Z","timestamp":1737726430000},"page":"307-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis"],"prefix":"10.1007","volume":"64","author":[{"given":"Celine","family":"Konecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mavrakanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-7889","authenticated-orcid":false,"given":"Zoubir","family":"Djerada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"1476_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56-528.","journal-title":"Circulation"},{"key":"1476_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373\u2013498.","journal-title":"Eur Heart J"},{"key":"1476_CR3","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1093\/ndt\/gfs416","volume":"27","author":"D Zimmerman","year":"2012","unstructured":"Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant. 2012;27:3816\u201322.","journal-title":"Nephrol Dial Transplant"},{"key":"1476_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/ki.2009.477","volume":"77","author":"V Wizemann","year":"2010","unstructured":"Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77:1098\u2013106.","journal-title":"Kidney Int"},{"key":"1476_CR5","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/ndt\/gfab060","volume":"37","author":"AS De Vriese","year":"2022","unstructured":"De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. Nephrol Dial Transplant. 2022;37:2072\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1476_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/jcph.633","volume":"56","author":"M Chang","year":"2016","unstructured":"Chang M, Yu Z, Shenker A, Wang J, Pursley J, Byon W, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56:637\u201345.","journal-title":"J Clin Pharmacol"},{"key":"1476_CR7","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022;146:1735\u201345.","journal-title":"Circulation"},{"key":"1476_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jha2.606","volume":"4","author":"CI Tseng","year":"2023","unstructured":"Tseng CI, Roddick AJ, Bottomley MJ, Shapiro S, Udayaraj U. Safety and pharmacokinetic profile of apixaban in end-stage renal disease: a real-world analysis. EJHaem. 2023;4:291\u20133.","journal-title":"EJHaem."},{"key":"1476_CR9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/ndt\/gfaa351","volume":"36","author":"I Van den Bosch","year":"2021","unstructured":"Van den Bosch I, Bouillon T, Verhamme P, Vanassche T, Jacquemin M, Coemans M, et al. Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. Nephrol Dial Transplant. 2021;36:884\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1476_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/jcph.628","volume":"56","author":"X Wang","year":"2016","unstructured":"Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628\u201336.","journal-title":"J Clin Pharmacol"},{"key":"1476_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/pharmaceutics15020665","volume":"15","author":"C Leven","year":"2023","unstructured":"Leven C, M\u00e9nard P, Gouin-Thibault I, Ballerie A, Lacut K, Ollier E, et al. Transferability of published population pharmacokinetic models for apixaban and rivaroxaban to subjects with obesity treated for venous thromboembolism: a systematic review and external evaluations. Pharmaceutics. 2023;15:665.","journal-title":"Pharmaceutics"},{"key":"1476_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.anrea.2016.08.016","volume":"2","author":"P Albaladejo","year":"2016","unstructured":"Albaladejo P, Bonhomme F, Blais N, Collet JP, Faraoni D, Fontana P, et al. Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP)-September 2015. Anesth R\u00e9anim. 2016;2:414\u201320.","journal-title":"Anesth R\u00e9anim."},{"key":"1476_CR13","first-page":"HIS.S407101","volume":"9s1","author":"T Sunkara","year":"2016","unstructured":"Sunkara T, Ofori E, Zarubin V, Caughey ME, Gaduputi V, Reddy M. Perioperative management of direct oral anticoagulants (DOACs): a systemic review. Health Serv Insights. 2016;9s1:HIS.S407101.","journal-title":"Health Serv Insights."},{"key":"1476_CR14","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1093\/eurheartj\/ehx403","volume":"38","author":"A Godier","year":"2017","unstructured":"Godier A, Dincq A-S, Martin A-C, Radu A, Leblanc I, Antona M, et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017;38:2431\u20139.","journal-title":"Eur Heart J"},{"key":"1476_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024;149:e1-156.","journal-title":"Circulation"},{"key":"1476_CR16","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1681\/ASN.2016090980","volume":"28","author":"TA Mavrakanas","year":"2017","unstructured":"Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:2241\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1476_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1159\/000513152","volume":"50","author":"M Murakami","year":"2021","unstructured":"Murakami M, Narita Y, Urata M, Ichigi M, Nakatani S, Kondo Y, et al. Improved formula for predicting hemodialyzability of intravenous and oral drugs. Blood Purif. 2021;50:865\u201375.","journal-title":"Blood Purif"},{"key":"1476_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10928-013-9302-8","volume":"40","author":"T Tatarinova","year":"2013","unstructured":"Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, et al. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn. 2013;40:189\u201399.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1476_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","volume":"34","author":"MN Neely","year":"2012","unstructured":"Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467\u201376.","journal-title":"Ther Drug Monit"},{"key":"1476_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115620","volume":"168","author":"M Geoffroy","year":"2023","unstructured":"Geoffroy M, Gozalo C, Konecki C, Pauvele L, Hittinger A, Pastorel N, et al. A new pharmacokinetic model of urinary methotrexate to assess adherence in rheumatoid arthritis. Biomed Pharmacother. 2023;168: 115620.","journal-title":"Biomed Pharmacother"},{"key":"1476_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/1358863X211047270","volume":"27","author":"GJ Merli","year":"2022","unstructured":"Merli GJ, Kraft WK, Eraso LH, Galanis T, Thomson LJ, Ouma GO, et al. Apixaban Discontinuation for Invasive Or major Surgical procedures (ADIOS): a prospective cohort study. Vasc Med. 2022;27:269\u201376.","journal-title":"Vasc Med"},{"key":"1476_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jth.13227","volume":"14","author":"JH Levy","year":"2016","unstructured":"Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:623\u20137.","journal-title":"J Thromb Haemost"},{"key":"1476_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/psp4.12347","volume":"7","author":"B Cirincione","year":"2018","unstructured":"Cirincione B, Kowalski K, Nielsen J, Roy A, Thanneer N, Byon W, et al. Population pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation. CPT Pharmacomet Syst Pharmacol. 2018;7:728\u201338.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1476_CR24","unstructured":"Bristol-Myers Squibb\/Pfizer. Eliquis product information. Available from: https:\/\/www.ema.europa.eu\/fr\/documents\/product-information\/eliquis-epar-product-information_fr.pdf. Accessed 8 Jan 2025."},{"key":"1476_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.34","volume":"3","author":"TA Leil","year":"2014","unstructured":"Leil TA, Frost C, Wang X, Pfister M, LaCreta F. Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. CPT Pharmacomet Syst Pharmacol. 2014;3: e136.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1476_CR26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/psp4.12184","volume":"6","author":"W Byon","year":"2017","unstructured":"Byon W, Sweeney K, Frost C, Boyd RA. Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism. CPT Pharmacomet Syst Pharmacol. 2017;6:340\u20139.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1476_CR27","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/bcp.13561","volume":"84","author":"S Ueshima","year":"2018","unstructured":"Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, et al. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018;84:1301\u201312.","journal-title":"Br J Clin Pharmacol"},{"key":"1476_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.dmpk.2019.10.005","volume":"35","author":"E Goto","year":"2020","unstructured":"Goto E, Horinaka S, Ishimitsu T, Kato T. Factor Xa inhibitors in clinical practice: comparison of pharmacokinetic profiles. Drug Metab Pharmacokinet. 2020;35:151\u20139.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1476_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12882-021-02248-7","volume":"22","author":"L Andrews","year":"2021","unstructured":"Andrews L, Benken S, Tan X, Wenzler E. Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy. BMC Nephrol. 2021;22:45.","journal-title":"BMC Nephrol"},{"key":"1476_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/clpt.2010.106","volume":"88","author":"TA Leil","year":"2010","unstructured":"Leil TA, Feng Y, Zhang L, Paccaly A, Mohan P, Pfister M. Quantification of apixaban\u2019s therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther. 2010;88:375\u201382.","journal-title":"Clin Pharmacol Ther"},{"key":"1476_CR31","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","volume":"141","author":"JW Stanifer","year":"2020","unstructured":"Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141:1384\u201392.","journal-title":"Circulation"},{"key":"1476_CR32","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de M\u00e9decine d\u2019Urgence, Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie-R\u00e9animation et m\u00e9decine p\u00e9ri-op\u00e9ratoire, Groupe d\u2019Int\u00e9r\u00eat en H\u00e9mostase P\u00e9ri-op\u00e9ratoire, Soci\u00e9t\u00e9 Fran\u00e7aise de Thrombose et d\u2019H\u00e9mostase. Guidelines on the management of anticoagulant in emergency setting. 2024. Available from: https:\/\/sfar.org\/gestion-de-lanticoagulation-dans-un-contexte-durgence\/. Accessed 29 Apr 2024."},{"key":"1476_CR33","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/fcp.12770","volume":"36","author":"A Gibert","year":"2022","unstructured":"Gibert A, Lanoisel\u00e9e J, Janisset L, Pernod G, Ollier E, Delavenne X. Development of a Bayesian estimation tool to determine the optimal duration of apixaban discontinuation before a high-bleeding risk procedure. Fundam Clin Pharm. 2022;36:898\u2013907.","journal-title":"Fundam Clin Pharm"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01476-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01476-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01476-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:47:47Z","timestamp":1738255667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01476-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01476-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"31 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Mavrakanas is supported from a Fonds de Recherche Sant\u00e9 Quebec (FRSQ) J1 Clinician Scholar award and a Kidney Research Scientist Core Education and National Training (KRESCENT) program New Investigator Award.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Celine Konecki, Mark L. Lipman, and Zoubir Djerada have no conflicts of interest that are directly relevant to the content of this article.\u00a0Prof. Mavrakanas has received speaker honoraria from Bayer, BMS Canada, Janssen, Astra Zeneca, and Pfizer, and has served on advisory boards for Boehringer Ingelheim, Bayer, GSK, and Servier outside the submitted work. He has also received research grants from Astra Zeneca and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The original study was performed in line with the principles of the Declaration of Helsinki and approval was granted by the Research Ethics Committee of the Jewish General Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"CK: conceptualisation, methodology, data curation, formal analysis, investigation, visualisation, writing (original draft). MLL: conceptualisation, methodology, data curation, investigation, resources, writing (review and editing). TAM: conceptualisation, methodology, data curation, investigation, resources, supervision, writing (review and editing). ZD: conceptualisation, methodology, data curation, formal analysis, investigation, supervision, writing (review and editing).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}